Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New ultrasound agent matches nuclear medicine

This article was originally published in Clinica

Executive Summary

Preclinical studies show that Acusphere's new ultrasound contrast agent has the potential to simplify contrast echocardiography because it can be detected continuously after bolus administration. Trials of AI-700 in dogs show that gas-filled synthetic polymer microspheres detect areas of low blood flow in the heart muscle, in high agreement with nuclear medicine, the current gold standard for detecting heart prefusion defects, say cardiologists at Tufts-New England Medical Center in Boston.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT077769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel